Thermo Fisher to acquire Clario from Astorg, Nordic Capital, Novo and Cinven for $8.875bn.

Thermo Fisher, a company specializing in life-science tools and biopharma services, agreed to acquire Clario, a provider of endpoint data solutions for clinical trials, from private equity firms Astorg, Nordic Capital, Novo and Cinven, for $8.875bn. “Clario is an outstanding strategic fit, enabling faster, more informed drug development through differentiated technology and data intelligence solutions. At Thermo Fisher, we come to work every day thinking about how we can further advance our customers’ important work, and by adding these high-growth capabilities, we will deliver even deeper clinical insights to our customers and further accelerate the digital transformation of clinical research,” Marc N. Casper, Thermo Fisher Scientific Chairman, President and CEO.